Halberd Corporation (HALB)
USD 0.0
(-8.33%)
USD 0.0
(-8.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 728.71 Thousand USD | -22.36% |
| 2023 | 938.64 Thousand USD | 25.99% |
| 2022 | 745 Thousand USD | 35.77% |
| 2021 | 548.71 Thousand USD | 89.66% |
| 2020 | 289.31 Thousand USD | -38.44% |
| 2019 | 469.94 Thousand USD | 0.0% |
| 2017 | 1.04 Million USD | -15.13% |
| 2016 | 1.22 Million USD | 0.0% |
| 2008 | 377.8 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 909.97 Thousand USD | -3.05% |
| 2024 Q4 | 728.71 Thousand USD | -18.72% |
| 2024 Q3 | 896.57 Thousand USD | 1.36% |
| 2024 Q2 | 884.58 Thousand USD | -2.79% |
| 2023 Q4 | 938.64 Thousand USD | -3.04% |
| 2023 Q2 | 952.33 Thousand USD | 6.56% |
| 2023 Q1 | 893.68 Thousand USD | 19.96% |
| 2023 FY | 938.64 Thousand USD | 25.99% |
| 2023 Q3 | 968.1 Thousand USD | 1.66% |
| 2022 Q4 | 745 Thousand USD | 17.42% |
| 2022 Q3 | 634.46 Thousand USD | -92.37% |
| 2022 Q2 | 8.31 Million USD | 1735.67% |
| 2022 Q1 | 453.13 Thousand USD | -13.8% |
| 2022 FY | 745 Thousand USD | 35.77% |
| 2021 Q4 | 525.69 Thousand USD | 88.02% |
| 2021 FY | 548.71 Thousand USD | 89.66% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q3 | 279.58 Thousand USD | 0.0% |
| 2020 FY | 289.31 Thousand USD | -38.44% |
| 2019 FY | 469.94 Thousand USD | 0.0% |
| 2017 FY | 1.04 Million USD | -15.13% |
| 2016 FY | 1.22 Million USD | 0.0% |
| 2009 Q2 | 257.52 Thousand USD | -46.04% |
| 2009 Q3 | 525.87 Thousand USD | 104.21% |
| 2009 Q1 | 477.24 Thousand USD | 26.32% |
| 2008 FY | 377.8 Thousand USD | 0.0% |
| 2008 Q4 | 377.8 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2556.359% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 92.302% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.994% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 9.901% |
| Rebus Holdings, Inc. | 5.24 Million USD | 86.098% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.765% |
| Qrons Inc. | 1.48 Million USD | 51.05% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 40.572% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.027% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1530.39% |
| Skye Bioscience, Inc. | 14.07 Million USD | 94.822% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.633% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 92.395% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -72.859% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.544% |
| Intellipharmaceutics International Inc. | 12 Million USD | 93.932% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 81.079% |
| Mesoblast Limited | 188.44 Million USD | 99.613% |
| Marizyme, Inc. | 26.67 Million USD | 97.268% |
| Genus plc | 485 Million USD | 99.85% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 87.528% |
| Pharming Group N.V. | 244.07 Million USD | 99.701% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 63.748% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 71.04% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 80.823% |
| ContraFect Corporation | 32.53 Million USD | 97.76% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 63.22% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 80.962% |
| IMV Inc. | 37.93 Million USD | 98.079% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 93.813% |
| MultiCell Technologies, Inc. | 1617.67 USD | -44947.445% |
| ONE Bio Corp. | 27.49 Million USD | 97.35% |
| Accustem Sciences Inc. | 1.07 Million USD | 32.478% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.059% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 65.546% |
| Q BioMed Inc. | 8.13 Million USD | 91.04% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.121% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 85.839% |
| Biomind Labs Inc. | 1.49 Million USD | 51.374% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.386% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 91.941% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 96.04% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 49.178% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -412.839% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -262.338% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 87.317% |
| GB Sciences, Inc. | 5.41 Million USD | 86.549% |
| Alpha Cognition Inc. | 7.16 Million USD | 89.829% |
| HST Global, Inc. | 593.59 Thousand USD | -22.764% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 42.128% |
| Enzolytics Inc. | 365.26 Million USD | 99.8% |
| Agentix Corp. | 2.51 Million USD | 70.974% |
| Resverlogix Corp. | 67.39 Million USD | 98.919% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 13.117% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.836% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 57.484% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 97.055% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 93.878% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 80.118% |
| AVAX Technologies, Inc. | 3.99 Million USD | 81.753% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2543.255% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.945% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -205.345% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 80.486% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -7.033% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 73.126% |
| Kadimastem Ltd | 3.5 Million USD | 79.208% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -988.794% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.55% |
| BioStem Technologies, Inc. | 15.9 Million USD | 95.418% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -56.815% |
| LadRx Corporation | 2.2 Million USD | 66.884% |
| Cell Source, Inc. | 15.8 Million USD | 95.39% |
| Regen BioPharma, Inc. | 5.45 Million USD | 86.648% |
| Regen BioPharma, Inc. | 5.45 Million USD | 86.648% |
| NovAccess Global Inc. | 7.86 Million USD | 90.73% |
| Affymax, Inc. | 8.87 Million USD | 91.785% |
| Itoco Inc. | 1.65 Million USD | 55.919% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 64.48% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 87.953% |
| Mobile Lads Corp. | 1.31 Million USD | 44.521% |
| CytoDyn Inc. | 127.89 Million USD | 99.43% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1643.389% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 53.477% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 93.402% |
| SYBLEU INC | 681.41 Thousand USD | -6.942% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 88.058% |
| International Stem Cell Corporation | 5.27 Million USD | 86.191% |
| Bioxytran, Inc. | 3.24 Million USD | 77.574% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -16.444% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 84.217% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.222% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 96.727% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 64.021% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 86.697% |
| Neutra Corp. | 973.52 Thousand USD | 25.147% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.488% |
| PureTech Health plc | 125.58 Million USD | 99.42% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 80.604% |
| IXICO plc | 1.9 Million USD | 61.652% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 96.45% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.295% |
| CSL Limited | 18.62 Billion USD | 99.996% |
| Cellectis S.A. | 249.36 Million USD | 99.708% |